Nektar Therapeutics
(NASDAQ:NKTR)|
5.28 -0.22 (-4.00%) Jan 09 - Close |
|
|
|
After-Hours 5.29 +0.01 (0.19%) Fri, 9 Jan 2009 7:40 PM
- Compare NKTR with:
- View: Line | Candlestick
Company Profile
Nektar Therapeutics
201 Industrial Road
San Carlos, CA 94070
United States - Map
Phone: (650) 631-3100
Fax: (650) 631-3150
Website: www.nektar.com
State of incorporation: Delaware
CEO: Howard W. Robin
Employees: 575
Sector: Other
Industry Group: Other
Industry: Other
Dev therapeutic prod using pulmonary drug delivery
A biopharmaceutical company that develops and enables differentiated therapeutics with its PEGylation and pulmonary drug development technology platforms.
Recent news for NKTR
-
PR Newswire - Jan 05 at 7:25 ET
-
EDGAR Online - Jan 02 at 4:48 ET
-
Biotech proves defensive against tough 2008 market
AP - Dec 31 2008 at 7:15 ET
-
Nektar completes $115M asset sale to Novartis
bizjournals.com - Dec 31 2008 at 2:05 ET
-
Nektar completes $115M technology sale to Novartis
AP - Dec 31 2008 at 10:08 ET
-
Nektar Announces Closing of Sale of Specific Pulmonary Delivery Assets to Novartis for $115 Million
PR Newswire - Dec 31 2008 at 9:31 ET
-
Biotech proves defensive against tough 2008 market
AP - Dec 31 2008 at 9:23 ET
-
Motley Fool - Dec 22 2008 at 3:13 ET
-
Why Pfizer's Insulin Inhaler Failed
Investor's Business Daily - Dec 15 2008 at 5:47 ET
-
Motley Fool - Dec 05 2008 at 1:59 ET
Member sentiment (?) Neutral
Recent opinions on NKTR
-
Top 40 Rated Emerging Bio-Pharma Stocks
Dec 25 2008 at 10:22 ET (By MikeHavRx)